(Q36580581)

15 August 2017

1 reference

title

Current and emerging pharmacotherapies for treating tobacco dependence (English)

1 reference

15 August 2017

0 references

2

Caryn Lerman

1 reference

15 August 2017

Robert A Schnoll

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

11

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

429-444

1 reference

Nicotine dependence in the United States: prevalence, trends, and smoking persistence

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Consistency or change in nicotine dependence according to the Fagerström Test for Nicotine Dependence over three years in a population sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine and non-nicotine smoking cessation pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Pharmacotherapy for nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nortriptyline for smoking cessation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A comparison of a nicotine sublingual tablet and placebo for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Treating tobacco dependence: state of the science and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Efficacy of a nicotine lozenge for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

High-dose nicotine patch therapy. Percentage of replacement and smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Precessation treatment with nicotine skin patch facilitates smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Tailoring nicotine replacement therapy: rationale and potential approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effects of nicotine gum dose by level of nicotine dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Individual differences in preferences for and responses to four nicotine replacement products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine patch and lozenge are effective for women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Unaided smoking cessation and predictors of failure to quit in a community sample: effects of gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Pharmacogenetics and nicotine addiction treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A randomized controlled trial of financial incentives for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Bupropion for smoking cessation : predictors of successful outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Mediating mechanisms for the impact of bupropion in smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Transdermal clonidine: therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Current pharmacological treatments for nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Psychological intervention and antidepressant treatment in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Smokers' interest in quitting and services received: using practice information to plan quality improvement and policy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Use of pharmacy data to evaluate smoking regulations' impact on sales of nicotine replacement therapies in New York City.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Toward a comprehensive long term nicotine policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Over-the-counter availability of nicotine replacement therapy and smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The effect of over-the-counter sales of the nicotine patch and nicotine gum on smoking cessation in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The benefits of switching smoking cessation drugs to over-the-counter status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Impact of UK policy initiatives on use of medicines to aid smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Direct telemarketing of smoking cessation interventions: will smokers take the call?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The impact of advertising on nicotine replacement therapy demand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine addiction and comorbidity with alcohol abuse and mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Is there a common molecular pathway for addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Neurobiology of the nicotine withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Advances in pharmacotherapy for tobacco dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Inhibition of monoamine oxidase B in the brains of smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Brain monoamine oxidase A inhibition in cigarette smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine and nonnicotine factors in cigarette addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A randomized trial of sertraline as a cessation aid for smokers with a history of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine patch and paroxetine for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Naltrexone and nicotine patch smoking cessation: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Naltrexone augments the effects of nicotine replacement therapy in female smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A randomized trial of naltrexone for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The GABA B receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Mechanisms of the antinociceptive action of gabapentin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Mecamylamine moderates cue-induced emotional responses in smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Safety and immunogenicity of a nicotine conjugate vaccine in current smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

CB1 receptor antagonists for the treatment of nicotine addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Topiramate in benzodiazepine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Topiramate in opiate withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

A pilot trial of topiramate for the treatment of cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Pharmacogenetics and psychopharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.429

10.1517/14728214.11.3.429

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference